One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume ® Drug-Coated Balloon for Anterior Urethral Strictures
The Optilume® drug-coated balloon (DCB) is a urethral dilation balloon with a paclitaxel coating that combines mechanical dilation for immediate symptomatic relief with local drug delivery to maintain urethral patency. The ROBUST III study is a randomized, single-blind trial evaluating the safety an...
Gespeichert in:
| Veröffentlicht in: | The Journal of urology Jg. 207; H. 4; S. 866 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.04.2022
|
| Schlagworte: | |
| ISSN: | 1527-3792, 1527-3792 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The Optilume® drug-coated balloon (DCB) is a urethral dilation balloon with a paclitaxel coating that combines mechanical dilation for immediate symptomatic relief with local drug delivery to maintain urethral patency. The ROBUST III study is a randomized, single-blind trial evaluating the safety and efficacy of the Optilume DCB against endoscopic management of recurrent anterior urethral strictures.
Eligible patients were adult males with anterior strictures ≤12Fr in diameter and ≤3 cm in length, at least 2 prior endoscopic treatments, International Prostate Symptom Score ≥11 and maximum flow rate <15 ml per second. A total of 127 subjects were enrolled at 22 sites. The primary study end point was anatomical success (≥14Fr by cystoscopy or calibration) at 6 months. Key secondary end points included freedom from repeat treatment, International Prostatic Symptom Score and peak flow rate. The primary safety end point included freedom from serious device- or procedure-related complications.
Baseline characteristics were similar between groups, with subjects having an average of 3.6 prior treatments and average length of 1.7 cm. Anatomical success for Optilume DCB was significantly higher than control at 6 months (75% vs 27%, p <0.001). Freedom from repeat intervention was significantly higher in the Optilume DCB arm. Immediate symptom and urinary flow rate improvement was significant in both groups, with the benefit being more durable in the Optilume DCB group. The most frequent adverse events included urinary tract infection, post-procedural hematuria and dysuria.
The results of this randomized controlled trial support that Optilume is safe and superior to standard direct vision internal urethrotomy/dilation for the treatment of recurrent anterior urethral strictures <3 cm in length. The Optilume DCB may serve as an important alternative for men who have had an unsuccessful direct vision internal urethrotomy/dilation but want to avoid or delay urethroplasty. |
|---|---|
| AbstractList | The Optilume® drug-coated balloon (DCB) is a urethral dilation balloon with a paclitaxel coating that combines mechanical dilation for immediate symptomatic relief with local drug delivery to maintain urethral patency. The ROBUST III study is a randomized, single-blind trial evaluating the safety and efficacy of the Optilume DCB against endoscopic management of recurrent anterior urethral strictures.PURPOSEThe Optilume® drug-coated balloon (DCB) is a urethral dilation balloon with a paclitaxel coating that combines mechanical dilation for immediate symptomatic relief with local drug delivery to maintain urethral patency. The ROBUST III study is a randomized, single-blind trial evaluating the safety and efficacy of the Optilume DCB against endoscopic management of recurrent anterior urethral strictures.Eligible patients were adult males with anterior strictures ≤12Fr in diameter and ≤3 cm in length, at least 2 prior endoscopic treatments, International Prostate Symptom Score ≥11 and maximum flow rate <15 ml per second. A total of 127 subjects were enrolled at 22 sites. The primary study end point was anatomical success (≥14Fr by cystoscopy or calibration) at 6 months. Key secondary end points included freedom from repeat treatment, International Prostatic Symptom Score and peak flow rate. The primary safety end point included freedom from serious device- or procedure-related complications.MATERIALS AND METHODSEligible patients were adult males with anterior strictures ≤12Fr in diameter and ≤3 cm in length, at least 2 prior endoscopic treatments, International Prostate Symptom Score ≥11 and maximum flow rate <15 ml per second. A total of 127 subjects were enrolled at 22 sites. The primary study end point was anatomical success (≥14Fr by cystoscopy or calibration) at 6 months. Key secondary end points included freedom from repeat treatment, International Prostatic Symptom Score and peak flow rate. The primary safety end point included freedom from serious device- or procedure-related complications.Baseline characteristics were similar between groups, with subjects having an average of 3.6 prior treatments and average length of 1.7 cm. Anatomical success for Optilume DCB was significantly higher than control at 6 months (75% vs 27%, p <0.001). Freedom from repeat intervention was significantly higher in the Optilume DCB arm. Immediate symptom and urinary flow rate improvement was significant in both groups, with the benefit being more durable in the Optilume DCB group. The most frequent adverse events included urinary tract infection, post-procedural hematuria and dysuria.RESULTSBaseline characteristics were similar between groups, with subjects having an average of 3.6 prior treatments and average length of 1.7 cm. Anatomical success for Optilume DCB was significantly higher than control at 6 months (75% vs 27%, p <0.001). Freedom from repeat intervention was significantly higher in the Optilume DCB arm. Immediate symptom and urinary flow rate improvement was significant in both groups, with the benefit being more durable in the Optilume DCB group. The most frequent adverse events included urinary tract infection, post-procedural hematuria and dysuria.The results of this randomized controlled trial support that Optilume is safe and superior to standard direct vision internal urethrotomy/dilation for the treatment of recurrent anterior urethral strictures <3 cm in length. The Optilume DCB may serve as an important alternative for men who have had an unsuccessful direct vision internal urethrotomy/dilation but want to avoid or delay urethroplasty.CONCLUSIONSThe results of this randomized controlled trial support that Optilume is safe and superior to standard direct vision internal urethrotomy/dilation for the treatment of recurrent anterior urethral strictures <3 cm in length. The Optilume DCB may serve as an important alternative for men who have had an unsuccessful direct vision internal urethrotomy/dilation but want to avoid or delay urethroplasty. The Optilume® drug-coated balloon (DCB) is a urethral dilation balloon with a paclitaxel coating that combines mechanical dilation for immediate symptomatic relief with local drug delivery to maintain urethral patency. The ROBUST III study is a randomized, single-blind trial evaluating the safety and efficacy of the Optilume DCB against endoscopic management of recurrent anterior urethral strictures. Eligible patients were adult males with anterior strictures ≤12Fr in diameter and ≤3 cm in length, at least 2 prior endoscopic treatments, International Prostate Symptom Score ≥11 and maximum flow rate <15 ml per second. A total of 127 subjects were enrolled at 22 sites. The primary study end point was anatomical success (≥14Fr by cystoscopy or calibration) at 6 months. Key secondary end points included freedom from repeat treatment, International Prostatic Symptom Score and peak flow rate. The primary safety end point included freedom from serious device- or procedure-related complications. Baseline characteristics were similar between groups, with subjects having an average of 3.6 prior treatments and average length of 1.7 cm. Anatomical success for Optilume DCB was significantly higher than control at 6 months (75% vs 27%, p <0.001). Freedom from repeat intervention was significantly higher in the Optilume DCB arm. Immediate symptom and urinary flow rate improvement was significant in both groups, with the benefit being more durable in the Optilume DCB group. The most frequent adverse events included urinary tract infection, post-procedural hematuria and dysuria. The results of this randomized controlled trial support that Optilume is safe and superior to standard direct vision internal urethrotomy/dilation for the treatment of recurrent anterior urethral strictures <3 cm in length. The Optilume DCB may serve as an important alternative for men who have had an unsuccessful direct vision internal urethrotomy/dilation but want to avoid or delay urethroplasty. |
| Author | Hagedorn, Judith C Erickson, Brad A Husmann, Douglas A Coutinho, Karl Carrier, Serge Elliott, Sean P Cantrill, Christopher H Robertson, Kaiser J Virasoro, Ramón DeSouza, Euclid Chevli, Kent DeLong, Jessica M Schlaifer, Amy Natale, Richard Ehlert, Michael J Te, Alexis E Dann, Jeffrey Olsson, Carl D'Anna, Richard Aube-Peterkin, Melanie Brandes, Steven B Morey, Allen Levin, Richard DiMarco, David |
| Author_xml | – sequence: 1 givenname: Sean P surname: Elliott fullname: Elliott, Sean P organization: University of Minnesota, Minneapolis, Minnesota – sequence: 2 givenname: Karl surname: Coutinho fullname: Coutinho, Karl organization: New Jersey Urology LLC, Millburn, New Jersey – sequence: 3 givenname: Kaiser J surname: Robertson fullname: Robertson, Kaiser J organization: Chesapeake Urology, Hanover, Maryland – sequence: 4 givenname: Richard surname: D'Anna fullname: D'Anna, Richard organization: Arkansas Urology, Little Rock, Arkansas – sequence: 5 givenname: Kent surname: Chevli fullname: Chevli, Kent organization: Western New York Urology Associates, Cheektowaga, New York – sequence: 6 givenname: Serge surname: Carrier fullname: Carrier, Serge organization: McGill University Health Center, Montreal, Quebec, Canada – sequence: 7 givenname: Melanie surname: Aube-Peterkin fullname: Aube-Peterkin, Melanie organization: McGill University Health Center, Montreal, Quebec, Canada – sequence: 8 givenname: Christopher H surname: Cantrill fullname: Cantrill, Christopher H organization: Urology San Antonio, San Antonio, Texas – sequence: 9 givenname: Michael J surname: Ehlert fullname: Ehlert, Michael J organization: Metro Urology, a division of Minnesota Urology, Woodbury, Minnesota – sequence: 10 givenname: Alexis E surname: Te fullname: Te, Alexis E organization: Weill Cornell Medicine, New York, New York – sequence: 11 givenname: Jeffrey surname: Dann fullname: Dann, Jeffrey organization: Advanced Urology Institute, Daytona Beach, Florida – sequence: 12 givenname: Jessica M surname: DeLong fullname: DeLong, Jessica M organization: Urology of Virginia PLLC, Virginia Beach, Virginia – sequence: 13 givenname: Steven B surname: Brandes fullname: Brandes, Steven B organization: Columbia University, New York, New York – sequence: 14 givenname: Judith C surname: Hagedorn fullname: Hagedorn, Judith C organization: University of Washington, Seattle, Washington – sequence: 15 givenname: Richard surname: Levin fullname: Levin, Richard organization: Chesapeake Urology Research Associates, Annapolis, Maryland – sequence: 16 givenname: Amy surname: Schlaifer fullname: Schlaifer, Amy organization: Academic Urology & Urogynecology of Arizona, Phoenix, Arizona – sequence: 17 givenname: Euclid surname: DeSouza fullname: DeSouza, Euclid organization: Adult and Pediatric Urology PC, Omaha, Nebraska – sequence: 18 givenname: David surname: DiMarco fullname: DiMarco, David organization: Oregon Urology Institute, Springfield, Oregon – sequence: 19 givenname: Brad A surname: Erickson fullname: Erickson, Brad A organization: University of Iowa Hospitals and Clinics, Iowa City, Iowa – sequence: 20 givenname: Richard surname: Natale fullname: Natale, Richard organization: Carolina Urology Partners PLLC, Concord, North Carolina – sequence: 21 givenname: Douglas A surname: Husmann fullname: Husmann, Douglas A organization: Mayo Clinic, Rochester, Minnesota – sequence: 22 givenname: Allen surname: Morey fullname: Morey, Allen organization: UT Southwestern Medical Center, Dallas, Texas – sequence: 23 givenname: Carl surname: Olsson fullname: Olsson, Carl organization: Integrated Medical Professionals, New York, New York – sequence: 24 givenname: Ramón surname: Virasoro fullname: Virasoro, Ramón organization: Urology of Virginia PLLC, Virginia Beach, Virginia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34854748$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtOwzAQQC1URD9wAiTkJZtAYif-LNtSoKhSpdIuWFVuMmmDHLvYDhJcgptwCE5GBEViNvMWb95i-qhjrAGEzpP4Koklv35YXcX_htCUHaFekhEeUS5J5x93Ud_75zhO0oyTE9SlqchSnooe-pgbiJ5AObwA3-jgcWkdDjvAi_lo9bjE0-kUL5QpbF29Q4HH1gRntW5x6Sql8eRV6UaFymx_rub7UOmmBvz1iW9cs43GVoVWHimtrTU_9aEJ4KoWVg7CzrWRx-CqPDQO_Ck6LpX2cHbYA7S6nSzH99FsfjcdD2dRTolgkSCcbhhhnNBSSCU3iSqA0zIvcgkqpykVPN9kLFNMxoQRKkXJhBQUKC1LnpMBuvzt7p19acCHdV35HLRWBmzj14TFWSZ5ktBWvTiozaaGYr13Va3c2_rvieQbgnF3SQ |
| CitedBy_id | crossref_primary_10_1002_bco2_312 crossref_primary_10_1097_JU_0000000000003568 crossref_primary_10_7759_cureus_82984 crossref_primary_10_7759_cureus_91919 crossref_primary_10_1007_s00120_023_02240_z crossref_primary_10_1111_bju_15831 crossref_primary_10_1038_s41467_023_38282_2 crossref_primary_10_1097_JU_0000000000003482 crossref_primary_10_1002_nau_25358 crossref_primary_10_1016_j_urology_2023_05_061 crossref_primary_10_1016_j_urology_2025_07_034 crossref_primary_10_1007_s11934_024_01235_3 crossref_primary_10_1007_s00345_023_04473_1 crossref_primary_10_3390_jcm14082854 crossref_primary_10_1007_s00345_023_04378_z crossref_primary_10_1016_j_euros_2025_03_002 crossref_primary_10_1002_bco2_241 crossref_primary_10_1007_s00261_022_03761_5 crossref_primary_10_1186_s12894_025_01896_3 crossref_primary_10_3390_surgeries6030059 crossref_primary_10_1016_j_urolvj_2024_100294 crossref_primary_10_1007_s11934_024_01202_y crossref_primary_10_1016_j_urology_2025_04_058 crossref_primary_10_1177_15579883231202714 crossref_primary_10_1007_s00345_023_04747_8 crossref_primary_10_1016_j_urology_2025_05_057 crossref_primary_10_1111_bju_16431 crossref_primary_10_1016_j_mjafi_2022_12_002 crossref_primary_10_1177_17562872241312522 crossref_primary_10_1055_a_2645_6997 crossref_primary_10_3390_jcm14072171 crossref_primary_10_1007_s00120_024_02369_5 crossref_primary_10_1186_s12894_025_01829_0 crossref_primary_10_1089_end_2024_0718 crossref_primary_10_1016_j_eururo_2022_04_011 crossref_primary_10_4103_aja202341 crossref_primary_10_1016_j_euf_2025_03_013 crossref_primary_10_1016_j_urology_2022_08_069 crossref_primary_10_3389_fruro_2024_1342941 crossref_primary_10_1089_end_2025_0332 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/JU.0000000000002346 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3792 |
| ExternalDocumentID | 34854748 |
| Genre | Randomized Controlled Trial Multicenter Study Journal Article |
| GroupedDBID | --- --K .55 .GJ .XZ 08P 0R~ 123 1B1 1CY 354 3O- 4.4 457 4G. 4Q1 4Q2 4Q3 53G 5RE 5VS 7-5 AAAAV AAEDT AAEDW AAGIX AAHPQ AAIQE AAJCS AAKAS AALRI AAMOA AAQFI AAQKA AAQQT AAQXK AASCR AASXQ AAXUO ABASU ABCQX ABDIG ABJNI ABLJU ABMAC ABOCM ABPPZ ABVCZ ABWVN ABXYN ABZZY ACGFS ACIJW ACILI ACLDA ACOAL ACRPL ACXJB ACZKN ADGGA ADHPY ADMUD ADNKB ADNMO ADZCM AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFFNX AFNMH AFTRI AFUWQ AGHFR AHOMT AHQNM AHQVU AHRYX AHVBC AI. AINUH AITUG AIZYK AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AMRAJ AOQMC ASGHL ASPBG AVWKF AZFZN BCGUY BELOY BYPQX C45 C5W CGR CS3 CUY CVF DIWNM DU5 EBS ECM EEVPB EIF EJD ERAAH EX3 F5P FCALG FDB FEDTE FGOYB GBLVA GNXGY GQDEL HLJTE HVGLF HZ~ H~9 IH2 IHE IKREB IKYAY IPNFZ J5H KMI L7B M41 MJL MO0 N4W NPM NQ- NTWIH O9- OAG OAH OB3 OBH ODMTH OGROG OHH OL1 OVD OWU OWV OWW OWY OWZ P2P QTD R2- RIG RLZ ROL RPZ SEL SES SJN SSZ TEORI TSPGW UDS UNMZH UV1 VH1 VVN WOW X7M XH2 XYM YFH YOC ZCG ZFV ZGI ZXP ZY1 ZZMQN 7X8 ABPXF ADKSD ADSXY |
| ID | FETCH-LOGICAL-c3286-8273b626723f89a9b1ade73fcdc9eac34387cb565a690262398f68983e33ff7c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 58 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000766306300027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-3792 |
| IngestDate | Mon Sep 08 05:02:35 EDT 2025 Thu Apr 03 07:02:37 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | urethral stricture lower urinary tract symptoms urinary bladder neck obstruction |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3286-8273b626723f89a9b1ade73fcdc9eac34387cb565a690262398f68983e33ff7c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&DO=10.1097/JU.0000000000002346 |
| PMID | 34854748 |
| PQID | 2605597113 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2605597113 pubmed_primary_34854748 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-Apr 20220401 |
| PublicationDateYYYYMMDD | 2022-04-01 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-Apr |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of urology |
| PublicationTitleAlternate | J Urol |
| PublicationYear | 2022 |
| References | 35014865 - J Urol. 2022 Apr;207(4):941-942 34963296 - J Urol. 2022 Apr;207(4):874-875 34963297 - J Urol. 2022 Apr;207(4):874 |
| References_xml | – reference: 34963296 - J Urol. 2022 Apr;207(4):874-875 – reference: 35014865 - J Urol. 2022 Apr;207(4):941-942 – reference: 34963297 - J Urol. 2022 Apr;207(4):874 |
| SSID | ssj0014572 |
| Score | 2.5833795 |
| Snippet | The Optilume® drug-coated balloon (DCB) is a urethral dilation balloon with a paclitaxel coating that combines mechanical dilation for immediate symptomatic... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 866 |
| SubjectTerms | Adult Coated Materials, Biocompatible Dilatation - adverse effects Dilatation - methods Humans Male Middle Aged Paclitaxel - administration & dosage Prospective Studies Recurrence Single-Blind Method Treatment Outcome Urethral Stricture - surgery |
| Title | One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume ® Drug-Coated Balloon for Anterior Urethral Strictures |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34854748 https://www.proquest.com/docview/2605597113 |
| Volume | 207 |
| WOSCitedRecordID | wos000766306300027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELXYhLiw74uMxNWisd3YOSEoIIqgRaVF5VTFzgQqQQJNy4GP4FP4CL6McZKKExISOUS-2Io8z-Nnz2QeIQce52DBq7JKJRRM-iBYULERM1VpbACxL_Ms37sr1Wjobje4KS_csjKtcuwTc0cdpdbdkR863o3k1_PE0csrc6pRLrpaSmhMkmmBVMahWnV_ogiymos3OeVWXEgBH1cdCtThZaeoXFg-XEj_d46Z7zXnC__9ykUyX7JMelzAYolMQLJMZq_LOPoK-WgmwO4R5LQF2ehpmFHkrhS5IG01Tzq3bVqv12krTKL0uf8OEa0VCe1P2Gw7xNKzskh48pD3aqLjcV7u65OeDkYPrJYihY3oiYvqp0k--LGzYB8bnQEMHwc4xq0TB3ABjGyVdM7P2rULViozMCu49plG0mPwKKS4iHUQBsYLI1AithHaN7RCCq2sQa4Y4uGb-67GYOzrQAsQIo6V5WtkKkkT2CDUQBwZUwFfcCuFwc1RcevKk3p4kAPtb5L98Uz3EPkunBEmkI6y3s9cb5L1wly9l6JER09IXZVK6q0_9N4mc9z905Cn4-yQ6RjXPeySGfs27GeDvRxS-G7cXH8Dup3V5Q |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=One-Year+Results+for+the+ROBUST+III+Randomized+Controlled+Trial+Evaluating+the+Optilume%C2%AE+Drug-Coated+Balloon+for+Anterior+Urethral+Strictures&rft.jtitle=The+Journal+of+urology&rft.au=Elliott%2C+Sean+P&rft.au=Coutinho%2C+Karl&rft.au=Robertson%2C+Kaiser+J&rft.au=D%27Anna%2C+Richard&rft.date=2022-04-01&rft.issn=1527-3792&rft.eissn=1527-3792&rft.volume=207&rft.issue=4&rft.spage=866&rft_id=info:doi/10.1097%2FJU.0000000000002346&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-3792&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-3792&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-3792&client=summon |